Publications by authors named "Michitsugu Kamezaki"
Article Synopsis
- * Researchers created a mouse model that mimics advanced DKD and found significant tissue damage, inflammation, and high levels of VCAM1 in the kidneys, which reflects the condition in humans.
- * The drug luseogliflozin was shown to improve kidney health by reducing tissue hypoxia and inflammation, highlighting the potential of VCAM1 as a marker and SGLT2 inhibitors as a treatment option for advanced DKD.
Background: Although superior vena cava (SVC) syndrome has also been reported as a late complication of pacemaker (PM) implantation, acute onset of SVC syndrome caused by disdialysis syndrome in patients with PM implantation is very rare. There are no specific therapies or guidelines.
Case Summary: A 96-year-old woman receiving dialysis was implanted with a PM due to sick sinus syndrome.
Article Synopsis
- Streptozotocin (STZ) is mainly used as an anti-cancer drug for treating neuroendocrine tumors (NETs) but can also cause DNA damage in kidney cells, leading to injury.
- Research showed that this kidney damage is linked to the activation of the p53 signaling pathway and reduced membrane transporters in tubular epithelial cells.
- Treatment with an SGLT2 inhibitor can help protect kidney cells from STZ-induced damage without affecting the drug's effectiveness on pancreatic β-cells, suggesting its potential as a preventative treatment for kidney injury in NET patients.
Based on recent clinical trials using sodium-glucose co-transporter 2 inhibitor (SGLT2i) demonstrating the significant improvement of outcomes of diabetic kidney disease (DKD), the paradigm shift from "glomerulocentric" to "tubule centric" pathophysiology in DKD progression has been highlighted. Several responsible mechanisms for renoprotective effects by SGLT2i have been proposed recently, but the changes in proximal tubule-specific gene expression by SGLT2i in diabetic mice have not been elucidated. We report the analysis of the proximal tubular-specific pathway, demonstrating the downregulation of oxidative phosphorylation in dapagliflozin-treated mice, a type 2 diabetic model.
View Article and Find Full Text PDFKidney hypertrophy is a common clinical feature in patients with diabetes and is associated with poor renal outcomes. Initial cell proliferation followed by cellular hypertrophy are considered the responsible mechanisms for diabetic kidney hypertrophy. However, whether similar responses against hyperglycemia continue in the chronic phase in diabetes is unclear.
View Article and Find Full Text PDFArticle Synopsis
- Sodium glucose co-transporter 2 inhibitors (SGLT2i), particularly ipragliflozin, are effective in slowing down the progression of diabetic kidney disease, as seen in various studies.
- Administering ipragliflozin to both type 2 and type 1 diabetic mice showed that it lowered blood glucose and urinary albumin levels, while also inhibiting kidney enlargement and reducing oxidative stress.
- The study highlighted that both high- and low doses of ipragliflozin protect kidney function by improving podocyte integrity and reducing renal tissue hypoxia, with dose-dependent effects particularly noted in the early stages of diabetic nephropathy.
A 62-year-old man exhibiting nasal obstruction and glomerulonephritis with proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCAs) was diagnosed with extranodal NK/T-cell lymphoma, nasal type (ENKL) with infiltration of neutrophils with apoptosis. Chemoradiotherapy reduced the tumor, improved the renal function, and decreased the PR3-ANCA levels. ANCA-positivity is observed in immunoinsufficient diseases, in which neutrophils lead to apoptosis and translocate intracellular granules, such as PR3, to the cell surface, triggering the production of ANCAs.
View Article and Find Full Text PDFArticle Synopsis
- HDR syndrome is a rare genetic disorder linked to mutations in the GATA3 gene, characterized by hypoparathyroidism, sensorineural deafness, and renal dysplasia.
- A new case of HDR syndrome was reported in an adult with a specific mutation (p.C288W) in GATA3, revealing unusual kidney histology similar to membranoproliferative glomerulonephritis.
- Further studies on kidney histology in HDR syndrome patients are essential to understand how GATA3 affects kidney development and function in adults.